The diagnostic impact of UK regional variations in age‐specific prostate‐specific antigen guidelines by Light, Alexander et al.
The diagnostic impact of UK regional variations in
age-specific prostate-specific antigen guidelines
The ideal prostate cancer diagnostic pathway would maximize
detection of clinically significant prostate cancer (csPCa)
while avoiding unnecessary biopsies and other investigations.
The introduction of pre-biopsy MRI has done much to aid
this goal. However, referrals into the image-based diagnostic
pathway still depend on PSA testing performed in primary
care and interpreted using referral guidelines. In the UK, the
National Institute for Health and Care Excellence (NICE)
only provides guidance on PSA thresholds for men aged
50–69 years (PSA ≥3.0 ng/mL) [1]. For other age groups,
PSA thresholds are set by regional cancer networks without
any unified consensus. In the present study, we explored if
different regional guidelines impacted csPCa detection in
modern image-based pathways.
We assembled a large English cohort of men investigated
between 2013 and 2020 using image-based diagnostics from
three geographically separate tertiary units. Through
correspondence we obtained current PSA referral guidelines
from 16 cancer networks in England and Wales. These
represented 10 discrete referral models, ranging from a single
PSA threshold to five-strata age-reference models. We applied
these models to our cohort to evaluate detection of Grade
Group 2 disease or higher (≥GG2). We calculated rates of
men avoiding referral, rates of missed diagnoses, and negative
predictive value (NPV). Men not meeting referral criteria
were assumed to have avoided further investigation. Analyses
were performed for the whole cohort and then stratified by
age ranges: <50 years; 50–59 years; 60–69 years; 70–79 years;
and ≥80 years.
A total of 2760 men were included, with a median age of
67 years and a median referral PSA level of 7.47 ng/mL.
≥GG2 cancers were detected in 38.7% of men, and no cancer
in 38.8%. Table 1 shows the referral criteria for the 10
models, plus our overall and age-stratified results. The 10
models varied considerably in avoided referrals when applied
to this cohort (6.5–14.6%). There was also considerable
variation in missed ≥GG2 diagnoses (2.6–11.5%) and NPV
(69.4–84.4%). On stratifying by age range, all models
performed better in younger men (≤59 years). For the age
range 50–59 years, this was attributable to all models using
the NICE-recommended PSA threshold of ≥3.0 ng/mL, or
>3.0 ng/mL. The rate of missed diagnoses in this age range
was 0–0.9%, and the NPV was 97.5–100%. For the age range
60–69 years, the 10 models performed reasonably well, with
low rates of missed diagnoses (2.5–4.8%), and high NPV
(82.2–85.1%). The greatest discrepancies were observed in
older men, reflecting greater heterogeneity in guidelines. For
the age range 70–79 years, rates of avoided referrals were as
high as 21.6% (range 6.1–21.6%), with rates of missed
diagnoses as high as 14.2% (range 3.1–14.2%). NPV in this
group was modest and variable (60.8–71.4%). For the age
group ≥80 years, there was even greater variation in avoided
referrals (4.7–71.9%), missed diagnoses (2.3–68.2%) and NPV
(34.8–75.0%).
These results suggest that different PSA age-reference
thresholds in current use may produce large geographical
variations in referral rates, missed diagnoses and NPV across
England and Wales. This is particularly evident in older men
where there is a conspicuous lack of national guidance. The
main limitation of this study is the use of a cohort comprising
men already referred to tertiary care, rather than an unfiltered
primary care cohort. Furthermore, these men would have been
subject to local PSA referral thresholds themselves, although we
have tried to mitigate this by combining data from three
regions. Nevertheless, these results do suggest a geographical
difference in how men are assessed. Crucially, where an
individual lives may determine whether they are referred and
investigated. It is certainly interesting to speculate how a lack of
central age-referenced PSA guidance could offset the diagnostic
advantages of pre-biopsy MRI. Specifically, the notion that MRI
enhances csPCa detection rates, balanced against the notion
that geographically different PSA models may reduce the
number of men referred for an MRI in the first place.
Current PSA age-reference ranges are based on historical,
cross-sectional measurements with limited implications for
modern diagnostics [2]. An analysis of men in the UK aged
50–69 years from the ProtecT trial identified that a single
PSA ≥3.0 ng/mL threshold (current NICE guidance) missed
0.1% of high-risk disease [3]. NICE guidance at the time of
their article writing (age 50–59 years: PSA ≥3.0 ng/mL; age
60–70 years: PSA ≥4.0 ng/mL; age ≥70 years: PSA ≥5.0 ng/
mL), and age-specific ranges from the Krimpen study resulted
in fewer biopsies, but unacceptable rates of missed high-risk
disease [4]. Notably, these men were investigated prior to
2009 using transrectal biopsy without pre-biopsy MRI. This
study aside, there is little novel research in this area. Further
work incorporating modern MRI-based diagnostic pathways
would be timely for informing contemporary PSA age-
reference ranges.
The optimal balance between maximizing diagnoses and
minimizing referrals is most unclear in older men, where
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treatment decisions are more complex. To derive benefit from
curative treatment, men with localized disease should have
≥10 years life expectancy, and be fit enough for the
treatments themselves [5]. Accordingly, high PSA thresholds
investigate fewer men and may miss more csPCa, on the
probable assumption that these men will be poor candidates
Table 1 Comparative model performance for all ages and further stratified by age range.
Model Referral criteria Age range, years Avoids referral, % Missed ≥GG2 cancer, % NPV for ≥GG2 cancer, %
1 Age <50 years: PSA >3.0 ng/mL
Age 50–59 years: PSA >3.0 ng/mL
Age 60–69 years: PSA >4.0 ng/mL
Age ≥70 years: PSA >5.0 ng/mL
All 9.5 4.6 81.4
<50 23.2 0.0 100.0
50–59 8.5 0.9 97.5
60–69 8.7 4.8 82.4
70–79 10.5 5.5 71.4
≥80 6.3 2.3 75.0
2 Age 50–59 years: PSA >3.0 ng/mL
Age 60–69 years: PSA >4.0 ng/mL
Age ≥70 years: PSA >5.0 ng/mL
All 11.1 5.5 80.4
<50 100.0 100.0 82.1
50–59 8.5 0.9 97.5
60–69 8.7 4.8 82.4
70–79 10.5 5.5 71.4
≥80 6.3 2.3 75.0
3 Age 40–49: PSA ≥2.5 ng/mL
Age 50–69 years: PSA ≥3.0 ng/mL
Age ≥70 years: PSA ≥5.0 ng/mL
All 7.8 3.7 81.2
<50 12.5 0.0 100.0
50–59 8.5 0.9 97.5
60–69 5.3 2.5 84.8
70–79 10.4 5.5 71.1
≥80 6.3 2.3 75.0
4 Age 40–49 years: PSA ≥2.5 ng/mL
Age 50–69 years: PSA ≥3.0 ng/mL
Age 70–79 years: PSA ≥5.0 ng/mL
All 9.9 7.8 81.3
<50 12.5 0.0 100.0
50–59 8.5 0.9 97.5
60–69 5.3 2.5 84.8
70–79 10.4 5.5 71.1
≥80 10.4 100.0 31.3
5 Age 50–69 years: PSA ≥3.0 ng/mL
Age ≥70 years: PSA ≥5.0 ng/mL
All 9.5 4.7 80.7
<50 100.0 100.0 82.1
50–59 8.5 0.9 97.5
60–69 5.4 2.5 84.8
70–79 10.4 5.5 71.1
≥80 6.3 2.3 75.0
6 Age <50 years: PSA >2.5 ng/mL
Age 50–69 years: PSA >3.0 ng/mL
Age 70–79 years: PSA >5.0 ng/mL
Age ≥80 years: PSA >10.0 ng/mL
All 8.4 4.8 77.9
<50 12.5 0.0 100.0
50–59 8.5 0.9 97.5
60–69 8.5 2.5 85.1
70–79 10.5 5.5 71.4
≥80 29.7 27.3 36.8
7 Age 40–49 years: PSA ≥2.5 ng/mL
Age 50–69 years: PSA ≥3.0 ng/mL
Age 70–75 years: PSA ≥4.0 ng/mL
Age 76–79 years: PSA ≥5.0 ng/mL
Age ≥80 years: PSA ≥10.0 ng/mL
All 7.5 4.3 77.6
<50 12.5 0.0 100.0
50–59 8.5 0.9 97.5
60–69 8.5 2.5 84.8
70–79 7.9 4.5 68.9
≥80 29.7 27.3 36.8
8 Any age: PSA >3.0 ng/mL All 6.5 2.6 84.4
<50 23.2 0.0 100.0
50–59 8.5 0.9 97.5
60–69 5.4 2.5 85.1
70–79 6.1 3.1 71.9
≥80 4.7 2.3 66.7
9 Age <50 years: PSA ≥2.0 ng/mL
Age 50–59 years: PSA ≥3.0 ng/mL
Age 60–69 years: PSA ≥4.0 ng/mL
Age 70–74 years: PSA ≥5.0 ng/mL
Age 75–80 years: PSA ≥7.5 ng/mL
All 13.3 11.3 73.4
<50 5.4 0.0 100.0
50–59 8.5 0.9 97.5
60–69 8.6 4.8 82.2
70–79 17.8 12.7 60.8
≥80 17.8 81.8 28.0
10 Age <50 years: PSA >2.5 ng/mL
Age 50–59 years: PSA >3.0 ng/mL
Age 60–69 years: PSA >4.0
Age 70–79 years: PSA >6.5 ng/mL
Age ≥80 years: PSA >20.0 ng/mL
All 14.6 11.5 69.4
<50 12.5 0.0 100.0
50–59 8.5 0.9 97.5
60–69 8.7 4.8 82.4
70–79 21.6 14.2 63.7
≥80 71.9 68.2 34.8
GG, Grade Group; NPV, negative predictive value.
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for curative treatment. By extension, it is also unreasonable to
subject these men to potentially harmful biopsies. However,
older men who do meet these high thresholds are more likely
to harbour locally advanced or metastatic disease that could
benefit from therapy irrespective of life expectancy or
comorbidity [5].
Developing new PSA thresholds will be challenging as this
needs to balance the risk of missed cancers versus over-
investigation, including unnecessary MRI and biopsies.
Higher thresholds miss more csPCa, but investigate fewer
men, whilst lower thresholds identify more csPCa through
investigating more men. For example, a single ≥3.0 ng/mL
threshold in the present study (model 8) led to the fewest
men avoiding referral (6.5%), but also the fewest missed
diagnoses (2.6%). In contrast, the five-strata model 10 led to
the most men avoiding referral (14.6%), but also the most
missed diagnoses (11.5%). A further consideration is whether
it is time to abandon age-reference PSA models and move to
alternative screening tests such as PSA density (PSA corrected
for prostate volume), novel biomarkers such as Prostate
Health Index (PHI) and 4K, or indeed primary MRI [6–8].
We have demonstrated that the use of different age-reference
PSA threshold guidelines across England and Wales may
produce geographical variation in referrals and csPCa
diagnostics. This argues for a single, national PSA referral
model to unify practice until new detection strategies are
adopted.
Acknowledgements
Vincent J. Gnanapragasam acknowledges infrastructure
support by the National Institute of Health Research (NIHR)
Cambridge Biomedical Research Centre (BRC-1215-20014).
The views expressed are those of the authors and not




Alexander Light1,2 , Nicholas Burns-Cox3 ,
Angus Maccormick3, Joseph John4 , John McGrath4
and Vincent J Gnanapragasam1,2,5
1Division of Urology, Department of Surgery, University of
Cambridge, 2Department of Urology, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, 3Department of
Urology, Somerset NHS Foundation Trust, Taunton,
4Department of Urology, Royal Devon and Exeter NHS
Foundation Trust, Exeter, and 5Cambridge Urology
Translational Research and Clinical Trials Office,
Addenbrooke’s Hospital, Cambridge, UK
References
1 National Institute for Health and Care Excellence. Prostate Cancer:
Information about PSA testing, 2017. Available at: https://cks.nice.org.uk/
topics/prostate-cancer/diagnosis/psa-testing/. Accessed February 2021
2 Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific
antigen in a community-based population of healthy men. Establishment
of age-specific reference ranges. JAMA 1993; 270: 860–4
3 Gilbert R, Tilling K, Martin RM et al. Developing new age-specific
prostate-specific antigen thresholds for testing for prostate cancer. Cancer
Causes Control 2018; 29: 383–8
4 Bosch JL, Tilling K, Bohnen AM, Donovan JL, Krimpen Study.
Establishing normal reference ranges for PSA change with age in a
population-based study: the Krimpen study. Prostate 2006; 66: 335–43
5 European Association of Urology. Prostate cancer, 2020. Available at:
https://uroweb.org/guideline/prostate-cancer. Accessed February 2021
6 Kim L, Boxall N, George A et al. Clinical utility and cost modelling of the
phi test to triage referrals into image-based diagnostic services for
suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
7 Darst BF, Chou A, Wan P et al. The four-Kallikrein panel is effective in
identifying aggressive prostate cancer in a multiethnic population. Cancer
Epidemiol Biomarkers Prev 2020; 29: 1381–8
8 Eldred-Evans D, Burak P, Connor MJ et al. Population-based prostate
cancer screening with magnetic resonance imaging or ultrasonography: the
IP1-PROSTAGRAM study. JAMA Oncol 2021; 7: 395
Correspondence: Vincent J Gnanapragasam, Cambridge
Urology Translational Research and Clinical Trials Office,
Cambridge, UK.
e-mail: vjg29@cam.ac.uk
Abbreviations: csPCa, clinically significant prostate cancer;
GG, Grade Group; NICE, National Institute for Health and
Care Excellence; NPV, negative predictive value.
© 2021 The Authors
BJU International published by John Wiley & Sons Ltd on behalf of BJU International 3
Research Communication
